Human IPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications

Overview

Journal Stem Cells Int

Publisher Wiley

Specialty Cell Biology

Date 2015 Dec 24

PMID 26697076

Citations 13

Authors

Maria Giuseppina Cefalo

Andrea Carai

Evelina Miele

Agnese Po

Elisabetta Ferretti

Angela Mastronuzzi

Isabelle M Germano

Affiliations

Soon will be listed here.

Abstract

Many central nervous system (CNS) diseases including stroke, spinal cord injury (SCI), and brain tumors are a significant cause of worldwide morbidity/mortality and yet do not have satisfying treatments. Cell-based therapy to restore lost function or to carry new therapeutic genes is a promising new therapeutic approach, particularly after human iPSCs became available. However, efficient generation of footprint-free and xeno-free human iPSC is a prerequisite for their clinical use. In this paper, we will first summarize the current methodology to obtain footprint- and xeno-free human iPSC. We will then review the current iPSC applications in therapeutic approaches for CNS regeneration and their use as vectors to carry proapoptotic genes for brain tumors and review their applications for modelling of neurological diseases and formulating new therapeutic approaches. Available results will be summarized and compared. Finally, we will discuss current limitations precluding iPSC from being used on large scale for clinical applications and provide an overview of future areas of improvement. In conclusion, significant progress has occurred in deriving iPSC suitable for clinical use in the field of neurological diseases. Current efforts to overcome technical challenges, including reducing labour and cost, will hopefully expedite the integration of this technology in the clinical setting.

Citing Articles

iPSC-derived exosomes as amphotericin B carriers: a promising approach to combat cryptococcal meningitis.

Zhao J, Fang W, Gao Y, Chen J, Wang G, Gu J Front Microbiol. 2025; 16:1531425.

PMID: 39996080 PMC: 11847882. DOI: 10.3389/fmicb.2025.1531425.

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.

Chehelgerdi M, Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M Mol Cancer. 2023; 22(1):189.

PMID: 38017433 PMC: 10683363. DOI: 10.1186/s12943-023-01873-0.

Neuroprotection of Stem Cells Against Ischemic Brain Injury: From Bench to Clinic.

Liu X, Jia X Transl Stroke Res. 2023; 15(4):691-713.

PMID: 37415004 PMC: 10771544. DOI: 10.1007/s12975-023-01163-3.

Use of Brain-Derived Stem/Progenitor Cells and Derived Extracellular Vesicles to Repair Damaged Neural Tissues: Lessons Learned from Connective Tissue Repair Regarding Variables Limiting Progress and Approaches to Overcome Limitations.

Hart D Int J Mol Sci. 2023; 24(4).

PMID: 36834779 PMC: 9958575. DOI: 10.3390/ijms24043370.

An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool.

Javaid N, Choi S Stem Cells Int. 2022; 2022:4537335.

PMID: 36187228 PMC: 9522500. DOI: 10.1155/2022/4537335.

References

Lee G, Papapetrou E, Kim H, Chambers S, Tomishima M, Fasano C . Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009; 461(7262):402-6. PMC: 2784695. DOI: 10.1038/nature08320. View

Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K . In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007; 448(7151):318-24. DOI: 10.1038/nature05944. View

Waibler Z, Anzaghe M, Frenz T, Schwantes A, Pohlmann C, Ludwig H . Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol. 2008; 83(4):1563-71. PMC: 2643777. DOI: 10.1128/JVI.01617-08. View

Jacobs B . Stemming the hype: what can we learn from iPSC models of Parkinson's disease and how can we learn it?. J Parkinsons Dis. 2014; 4(1):15-27. DOI: 10.3233/JPD-130268. View

Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T . Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2007; 26(1):101-6. DOI: 10.1038/nbt1374. View

Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K . Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 2008; 1(1):55-70. DOI: 10.1016/j.stem.2007.05.014. View

Nakamura M, Tsuji O, Nori S, Toyama Y, Okano H . Cell transplantation for spinal cord injury focusing on iPSCs. Expert Opin Biol Ther. 2012; 12(7):811-21. DOI: 10.1517/14712598.2012.681774. View

Si-Tayeb K, Noto F, Sepac A, Sedlic F, Bosnjak Z, Lough J . Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev Biol. 2010; 10:81. PMC: 2923111. DOI: 10.1186/1471-213X-10-81. View

Warren L, Wang J . Feeder-free reprogramming of human fibroblasts with messenger RNA. Curr Protoc Stem Cell Biol. 2014; 27:4A.6.1-4A.6.27. DOI: 10.1002/9780470151808.sc04a06s27. View

10.

Benveniste R, Keller G, Germano I . Embryonic stem cell-derived astrocytes expressing drug-inducible transgenes: differentiation and transplantion into the mouse brain. J Neurosurg. 2005; 103(1):115-23. DOI: 10.3171/jns.2005.103.1.0115. View

11.

Thomalla G, Sobesky J, Kohrmann M, Fiebach J, Fiehler J, Zaro Weber O . Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke. 2007; 38(2):313-8. DOI: 10.1161/01.STR.0000254565.51807.22. View

12.

Binello E, Germano I . Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol. 2011; 14(3):256-65. PMC: 3280798. DOI: 10.1093/neuonc/nor204. View

13.

Fukusumi H, Shofuda T, Kanematsu D, Yamamoto A, Suemizu H, Nakamura M . Feeder-free generation and long-term culture of human induced pluripotent stem cells using pericellular matrix of decidua derived mesenchymal cells. PLoS One. 2013; 8(1):e55226. PMC: 3561375. DOI: 10.1371/journal.pone.0055226. View

14.

Sun N, Lee A, Wu J . Long term non-invasive imaging of embryonic stem cells using reporter genes. Nat Protoc. 2009; 4(8):1192-201. PMC: 3683546. DOI: 10.1038/nprot.2009.100. View

15.

Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448(7151):313-7. DOI: 10.1038/nature05934. View

16.

Donnan P, Dorward D, Mutch B, Morris A . Development and validation of a model for predicting emergency admissions over the next year (PEONY): a UK historical cohort study. Arch Intern Med. 2008; 168(13):1416-22. DOI: 10.1001/archinte.168.13.1416. View

17.

Germano I, Binello E . Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside. J Neurooncol. 2009; 93(1):79-87. PMC: 11766529. DOI: 10.1007/s11060-009-9869-5. View

18.

Ito D, Okano H, Suzuki N . Accelerating progress in induced pluripotent stem cell research for neurological diseases. Ann Neurol. 2012; 72(2):167-74. DOI: 10.1002/ana.23596. View

19.

Evans M, Kaufman M . Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981; 292(5819):154-6. DOI: 10.1038/292154a0. View

20.

Rideout 3rd W, Hochedlinger K, Kyba M, Daley G, Jaenisch R . Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell. 2002; 109(1):17-27. DOI: 10.1016/s0092-8674(02)00681-5. View